Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01801 INNOVENT BIO
RTNominal down87.050 -1.650 (-1.860%)
Research Report

10/06/2025 14:42

J.P. Morgan raises Innovent Bio to HKD84

  [ET Net News Agency, 10 June 2025] J.P. Morgan raised the target price for Innovent Bio (01801) to HKD84 from HKD74 and maintained the "overweight" rating.
  The research house said after IBI363's better-than-expected OS data at ASCO '25 boosted Innovent's share price, it expects ongoing clinical catalysts to further drive performance. (rc)

Back to Research Report

Remark: Real time quote last updated: 13/05/2026 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.